sever
acut
respiratori
syndrom
sar
newli
discover
acut
respiratori
infect
also
call
infecti
atyp
pneumonia
iap
domest
pathogen
new
coronaviru
differ
viru
viru
famili
bodi
human
be
anim
name
sarscov
till
clear
infect
chart
prevail
rule
sarscov
order
find
chang
rule
clinic
sar
case
serum
specif
igg
antibodi
whether
inappar
infect
health
popul
studi
adopt
indirect
immunofluoresc
assay
diagnosi
reagent
develop
institut
microb
epidem
academi
militari
iatrolog
scienc
antigen
captur
enzymelink
immunosorb
assay
bioindustri
research
institut
academi
militari
iatrolog
scienc
result
follow
sar
serum
sampl
belong
infector
hospit
respect
gener
hospit
guangzhou
militari
region
hospit
zhongsan
univers
hospit
guangdong
provinc
peopl
hospit
guangzhou
municip
peke
tini
tang
mount
hospit
feb
mar
healthi
sampl
servicemen
quarter
hongkong
quarter
macao
jun
medic
practition
around
peke
close
contact
sar
infector
healthi
bodi
check
person
guangzhou
serum
sampl
examin
method
indirect
ifa
elisa
doubleantigen
sandwich
describ
sarscov
nucleocaspid
antigen
geneindustri
method
indirect
ifa
dilut
prepar
serum
extinct
minut
dilut
draw
ul
drop
differ
hole
antigen
piec
set
neg
posit
compar
serum
warm
cultur
min
pb
shake
wash
time
mix
isothiocyan
acid
luciferin
warm
cultur
min
pb
wash
time
observ
fluoresc
microscop
antigen
captur
enzymelink
immunosorb
assay
establish
detect
antin
protein
antibodi
present
sera
volum
serum
ad
well
coat
recombin
n
protein
plate
incub
min
wash
five
time
phosphatebuff
salin
contain
tween
volum
label
antigen
ad
plate
incub
anoth
min
wash
alreadi
describ
tmb
substrat
solut
tetramethybenzidin
hydrochlorideml
acet
buffer
ad
mixtur
incub
min
reaction
termin
ad
n
sulfur
acid
absorb
nm
determin
sampl
averag
standard
deviat
sampl
healthi
peopl
consid
posit
examin
serum
healthi
peopl
method
doubleantigen
sandwich
elisa
found
one
posit
respect
servicemen
hong
kong
garrison
servicemen
macao
garrison
test
two
posit
sampl
method
ifa
found
neg
detect
health
care
worker
peke
elisa
find
neg
detect
healthi
peopl
guangzhou
area
method
elisa
ifa
result
neg
detail
result
list
tabl
trace
patient
serum
antibodi
use
elisa
ifa
found
first
ten
day
diseas
serum
sampl
case
got
posit
antibodi
posit
rate
case
posit
ifa
posit
rate
within
day
diseas
sampl
detect
elisa
ifa
posit
rate
day
later
posit
rate
separ
elasa
ifa
sampl
earli
period
diseas
posit
rate
detect
ifa
slightli
lower
elisa
result
got
close
day
diseas
result
show
meaning
detect
serum
igg
antibodi
day
clinic
diagnosi
patient
sar
antibodi
posit
result
detail
tabl
sar
case
diagnos
elisa
follow
case
onset
diseas
day
result
show
serum
igg
antibodi
titer
lift
time
went
first
month
patient
antibodi
lift
top
month
reach
peak
month
part
began
drop
still
keep
posit
two
year
figur
figur
far
know
noth
sar
came
infect
epidemiolog
rule
seroepidemiolog
studi
import
method
studi
infecti
diseas
preval
rule
order
cogniz
roundli
rule
serum
igg
antibodi
infect
chart
onset
sar
indirect
immunofluoresc
assay
ifa
doubleantigen
sandwich
enzymelink
immunosorb
assay
elisa
use
detect
sera
includ
healthi
popul
sar
patient
guangzhou
peke
elisa
method
use
detect
serum
sampl
healthi
popul
includ
close
contact
sar
patient
show
posit
sarscov
igg
due
fals
posit
result
elisa
valid
two
posit
sarscov
igg
serum
ifa
find
result
neg
nt
find
posit
antibodi
serum
guangzhou
district
use
ifa
elisa
made
clear
recess
infecti
sar
health
peopl
studi
result
show
clinic
sar
infect
patient
feb
mar
least
could
confirm
serolog
method
howev
may
miss
mani
case
detect
sarscov
igg
antibodi
serolog
method
earli
stage
diseas
first
day
ten
day
later
serum
antibodi
appear
patient
result
ifa
elisa
ident
studi
got
conclus
serolog
method
especi
ifa
great
diagnost
valu
dubiou
patient
diagnos
clinic
epidemiolog
therefor
doubl
serum
detect
obvious
necessari
sar
lab
diagnosi
detect
sar
patient
day
onset
sar
found
serum
antibodi
titer
increas
steadili
month
antibodi
patient
reach
peak
month
last
month
antibodi
patient
began
descend
reach
peak
though
antibodi
could
detect
posit
day
titer
declin
studi
put
forward
durat
sarscov
igg
would
last
year
trace
fall
curv
sarscov
igg
antibodi
